Free Trial
NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

Teva Pharmaceutical Industries logo
$17.11 -0.26 (-1.50%)
(As of 05:20 PM ET)

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Key Stats

Today's Range
$17.02
$17.50
50-Day Range
$17.10
$18.97
52-Week Range
$8.55
$19.31
Volume
6.32 million shs
Average Volume
9.27 million shs
Market Capitalization
$19.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.67
Consensus Rating
Moderate Buy

Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Teva Pharmaceutical Industries Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
56th Percentile Overall Score

TEVA MarketRank™: 

Teva Pharmaceutical Industries scored higher than 56% of companies evaluated by MarketBeat, and ranked 444th out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Teva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Teva Pharmaceutical Industries has only been the subject of 3 research reports in the past 90 days.

  • Read more about Teva Pharmaceutical Industries' stock forecast and price target.
  • Earnings Growth

    Earnings for Teva Pharmaceutical Industries are expected to grow by 13.68% in the coming year, from $2.34 to $2.66 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Teva Pharmaceutical Industries is -20.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Teva Pharmaceutical Industries is -20.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Teva Pharmaceutical Industries has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Teva Pharmaceutical Industries has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Teva Pharmaceutical Industries' valuation and earnings.
  • Percentage of Shares Shorted

    1.60% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.
  • Short Interest Ratio / Days to Cover

    Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Teva Pharmaceutical Industries has recently decreased by 9.14%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Teva Pharmaceutical Industries does not currently pay a dividend.

  • Dividend Growth

    Teva Pharmaceutical Industries does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.60% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.
  • Short Interest Ratio / Days to Cover

    Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Teva Pharmaceutical Industries has recently decreased by 9.14%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Teva Pharmaceutical Industries has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 32 news articles for Teva Pharmaceutical Industries this week, compared to 8 articles on an average week.
  • Search Interest

    41 people have searched for TEVA on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Teva Pharmaceutical Industries insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.55% of the stock of Teva Pharmaceutical Industries is held by insiders.

  • Percentage Held by Institutions

    54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Teva Pharmaceutical Industries' insider trading history.
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

Equities Analysts Offer Predictions for TEVA FY2024 Earnings
Could this stock soar as high as 1,000% under Trump?
33-year Wall Street veteran Dylan Jovine says there is one stock that could soar as high as 1,000% or more with Trump in office. And it's all because of a $45.7 trillion crisis the Democrats have created - and are likely to blame on our new President.
Teva selloff brings good entry point, says UBS
See More Headlines

TEVA Stock Analysis - Frequently Asked Questions

Teva Pharmaceutical Industries' stock was trading at $10.44 at the beginning of the year. Since then, TEVA stock has increased by 64.1% and is now trading at $17.13.
View the best growth stocks for 2024 here
.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings results on Wednesday, November, 8th. The company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. Teva Pharmaceutical Industries's revenue for the quarter was up 8.3% on a year-over-year basis.

Teva Pharmaceutical Industries' top institutional investors include Clal Insurance Enterprises Holdings Ltd (3.05%), Migdal Insurance & Financial Holdings Ltd. (2.25%), AustralianSuper Pty Ltd (0.70%) and Swiss National Bank (0.30%). Insiders that own company stock include Roberto Mignone, Mark Sabag, Sven Dethlefs, Eliyahu Sharon Kalif, Richard D Francis, David Matthew Stark, Eric A Hughes, Amir Weiss, Eric Drape, Hafrun Fridriksdottir, Eli Shani and Vikki L Conway.
View institutional ownership trends
.

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD) and AT&T (T).

Company Calendar

Last Earnings
11/08/2023
Today
11/12/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/29/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Employees
37,851
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.67
High Stock Price Target
$26.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+13.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-559,000,000.00
Pretax Margin
-3.16%

Debt

Sales & Book Value

Annual Sales
$15.85 billion
Cash Flow
$3.56 per share
Book Value
$5.63 per share

Miscellaneous

Outstanding Shares
1,132,910,000
Free Float
1,126,678,000
Market Cap
$19.58 billion
Optionable
Optionable
Beta
0.87

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:TEVA) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners